AnaptysBio IPO

1/27/2017

IPO

$75,000,000

We currently intend to use the net proceeds we receive from this offering, together with our existing cash and cash equivalents, as follows: approximately $25.0 million to fund development of ANB020 and ANB019 through initial clinical trials intended to demonstrate efficacy in multiple indications; approximately $15.0 million to fund continued development of other wholly-owned product candidates, including our checkpoint receptor agonist antibodies, and discovery of new product candidates to further expand our proprietary pipeline; and any remaining amounts to fund working capital, including general corporate purposes.

Publicly-held

Biopharmaceutical

10421 Pacific Center Ct. 200
San Diego, CA 92121
USA

AnaptysBio (NASDAQ: ANAB) is a leading biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology.